SCHEMBL8174653

SCHEMBL8174653

CN(c1cccc(Cn2cc(CC(=O)O)c3ccccc32)c1)c1ccccc1C(F)(F)F

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.57
ALDH1A1 P00352 3/20 0.57
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CDC25A P30304 1/20 0.42
HTR6 P50406 2/20 0.42
PLK1 P53350 1/20 0.42
ICMT O60725 6/20 0.42
FNTA P49354 2/20 0.41
FNTB P49356 2/20 0.41
PPARG P37231 2/20 0.40
PPARD Q03181 2/20 0.40
PPARA Q07869 2/20 0.40
CHRNB2 P17787 1/20 0.40
CHRNA7 P36544 1/20 0.40
CHRNA4 P43681 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8174714 0.91 LMNA (0.53) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL8178979 0.91 LMNA (0.53) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL8175107 0.90 ALDH1A1 (0.52) LMNAALDH1A1SMN1; SMN2CDC25AHTR6
SCHEMBL8172865 0.89 LMNA (0.55) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL8167250 0.89 LMNA (0.43) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL8186828 0.88 LMNA (0.54) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL8174532 0.88 LMNA (0.60) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL8167201 0.88 LMNA (0.60) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL13931029 0.87 LMNA (0.69) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL8180745 0.87 LMNA (0.59) LMNAALDH1A1SMN1; SMN2NPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 US disclosed
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 US disclosed
WO-2008100867-A2 NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, HCCS LMNA 2969/4885ALDH1A1 1836/4885SMN1; SMN2 2901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.